Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q13702
UPID:
RAPSN_HUMAN
Alternative names:
43 kDa postsynaptic protein; Acetylcholine receptor-associated 43 kDa protein; RING finger protein 205
Alternative UPACC:
Q13702; Q8TDF3; Q9BTD9
Background:
The 43 kDa receptor-associated protein of the synapse plays a pivotal role in neuromuscular junctions, specifically in the clustering of nicotinic acetylcholine receptors (nAChRs). This postsynaptic protein, also known as Acetylcholine receptor-associated 43 kDa protein and RING finger protein 205, is essential for linking the receptor to the cytoskeleton, facilitating synaptic transmission.
Therapeutic significance:
Linked to congenital myasthenic syndrome 11 and fetal akinesia deformation sequence 2, this protein's dysfunction underscores its critical role in neuromuscular diseases. Understanding its function and the genetic variants affecting it could lead to targeted therapies for these debilitating conditions.